Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M4,146Revenue $M1,503Net Margin (%)11.5Z-Score6.6
Enterprise Value $M3,976EPS $2.7Operating Margin %13.5F-Score6
P/E(ttm))25.1Cash Flow Per Share $0Pre-tax Margin (%)13.5Higher ROA y-yY
Price/Book4.410-y EBITDA Growth Rate %-1.1Quick Ratio1.5Cash flow > EarningsN
Price/Sales2.95-y EBITDA Growth Rate %12.0Current Ratio1.5Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %49.8ROA % (ttm)11.4Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)17.9Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M60.1ROI % (ttm)0Gross Margin Increase y-yY

Gurus Latest Trades with ICLR

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ICLRJean-Marie Eveillard 2014-06-30 Sold Out $37.92 - $48.97
($43.12)
$ 68.9837%Sold Out0
ICLRRon Baron 2013-09-30 Add0.05%$36.24 - $40.67
($38.49)
$ 68.9844%Add 25.15%1,280,000
ICLRRon Baron 2013-06-30 Add0.04%$29.2 - $36.22
($32.9)
$ 68.9852%Add 24.31%1,022,800
ICLRMeridian Funds 2013-03-31 Reduce-0.17%$27.25 - $32.91
($29.87)
$ 68.9857%Reduce -33.19%308,000
ICLRRon Baron 2013-03-31 Buy 0.15%$27.25 - $32.91
($29.87)
$ 68.9857%New holding822,800
ICLRMeridian Funds 2012-12-31 Reduce-0.16%$23.46 - $28.54
($26.39)
$ 68.9862%Reduce -28.22%461,000
ICLRMeridian Funds 2012-06-30 Add0.1%$20.51 - $23.23
($21.82)
$ 68.9868%Add 24.87%642,200
ICLRMeridian Funds 2012-03-31 Add0.06%$17.06 - $22.01
($19)
$ 68.9872%Add 25.16%514,300
ICLRJean-Marie Eveillard 2011-09-30 Add$16.5 - $25.21
($20.62)
$ 68.9870%Add 36.36%15,000
ICLRMeridian Funds 2011-06-30 Buy 0.24%$21.18 - $25.92
($24.03)
$ 68.9865%New holding351,000
ICLRJean-Marie Eveillard 2010-12-31 Add$19.22 - $22.22
($20.61)
$ 68.9870%Add 37.50%11,000
ICLRGeorge Soros 2010-09-30 Sold Out -0.03%$21.7 - $27.69
($24.14)
$ 68.9865%Sold Out0
ICLRJean-Marie Eveillard 2010-06-30 Reduce$26.2 - $29.99
($27.9)
$ 68.9860%Reduce -42.86%8,000
ICLRGeorge Soros 2010-03-31 Add$21.61 - $27.27
($24.53)
$ 68.9864%Add 27.15%28,100
ICLRGeorge Soros 2009-12-31 Add0.01%$21.23 - $26.24
($23.21)
$ 68.9866%Add 169.51%22,100
ICLRGeorge Soros 2009-09-30 Buy $20.87 - $24.68
($22.71)
$ 68.9867%New holding8,200
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ICLR is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


ICLR: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about ICLR :

    Quarterly/Annual Reports about ICLR:

      News about ICLR:

      Articles On GuruFocus.com
      Probable Gainers Of A European Market Bounce Back Jan 26 2015 
      Meridian Funds Comments on Icon PLC Dec 17 2014 
      Meridian Contrarian Fund 3Q 2014 Commentary Dec 17 2014 
      Baron Funds Comments on ICON PLC Jun 10 2013 
      Parexcel: Great Growth but a Tough Business Aug 17 2011 
      Weekly Guru Bargains Highlights: SD, CREE, AMLN, ICLR, CVD Nov 07 2010 
      ICON publie ses orientations financières pour l’année 2009 et les mises à jour des orientations Jan 09 2009 
      Resumen: ICON presenta previsiones financieras para 2009 y actualiza las de 2008 Jan 09 2009 
      Samenvatting: ICON publiceert cijfers voor 2009 en werkt cijfers 2008 bij Jan 09 2009 
      ICON veröffentlicht Ergebniserwartung für 2009 und aktualisiert Erwartung für 2008 (NASDAQ:ICLR) Jan 09 2009 


      More From Other Websites
      Cancer Genetics (CGIX) Shows Strength: Stock Gains 5.8% - Tale of the Tape Apr 13 2015
      New Book by Industry Thought Leaders Advocates for Re-Engineering Clinical Trials Apr 13 2015
      New Book by Industry Thought Leaders Advocates for Re-Engineering Clinical Trials Apr 13 2015
      New Book by industry Thought Leaders Advocates for Re-Engineering Clinical Trials Apr 13 2015
      MedAssets: A Strong Sell on Tepid View, Estimate Revision - Analyst Blog Apr 09 2015
      Air Methods Now a Strong Buy: Is It in Your Portfolio? - Analyst Blog Mar 27 2015
      Is ICON Public Limited (ICLR) a Great Growth Stock? - Tale of the Tape Mar 24 2015
      ICON and Carnegie Mellon University Collaborate to Evaluate Patient-centric Informed Consent... Mar 23 2015
      ICON and Carnegie Mellon University Collaborate to Evaluate Patient-centric Informed Consent... Mar 23 2015
      Biogen, Five Other Top Stocks Show No Sign Of Slowing Mar 20 2015
      ICON PLC Financials Mar 19 2015
      Why ICON Public Limited (ICLR) Could Beat Earnings Estimates Again - Tale of the Tape Mar 19 2015
      ICON Launches Medical Device, Diagnostics Research Group - Analyst Blog Mar 12 2015
      ICON Raised to Strong Buy on Stellar Q4, Strategic Acquisition - Analyst Blog Mar 11 2015
      ICON Launches Medical Device & Diagnostics Research Group Mar 09 2015
      ICON Launches Medical Device & Diagnostics Research Group Mar 09 2015
      Irish Highlanders: Drug Stocks Mallinckrodt, Horizon Pharma Rally Mar 05 2015
      ICON Plc (ICLR) Shares March Higher, Can It Continue? - Tale of the Tape Mar 05 2015
      ICON (ICLR) Posts Stellar Q4 Earnings, Revenues Rise Y/Y - Analyst Blog Mar 03 2015
      3 Healthcare Services Stocks Poised to Outperform in 2015 - Stocks in the News Mar 02 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      FEEDBACK